Biden's Latest Rx Pricing Moves Are At Once Bold And Incremental

As the president’s reelection campaign themes take shape, the administration is preparing to leverage NIH patents in ways it had previously eschewed. As with the merger oversight effort, though, the germs of the plans began earlier in Biden’s tenure.

March-In Rights Have Never Been Used To Lower Drug Prices • Source: Shutterstock

President Biden’s new prescription drug pricing efforts seem part of reelection strategy intended to highlight an area, healthcare, where the public has long held more favorable views of Democrats. But the initiative itself includes an aggressive exploration of patent “march-in” rights that has been rejected by previous Democratic administrations – and even the Biden team itself.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Drug Pricing

More from Scrip

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By 

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies